From GlobeNewswire: 2025-02-28 16:05:00

4D Molecular Therapeutics reported positive interim data for 4D-150 in wet AMD and DME, with ongoing Phase 3 trials. The company’s 4FRONT program is on track, with topline data expected in 2027. The pipeline is focused on optimizing resources for product candidates like 4D-150 and 4D-710. The company has $505 million in cash as of December 31, 2024, to fund operations into 2028.

In the ophthalmology portfolio, 4D-150 showed positive 52-week results in wet AMD, reducing injection burden and maintaining visual acuity. The Phase 3 program for 4D-150 in wet AMD is expected to enroll patients rapidly, with topline results in late 2027. Positive interim data was also reported for 4D-150 in DME, with FDA alignment for a single Phase 3 trial.

In the pulmonology program, enrollment for 4D-710 in CF lung disease is ongoing. Expected upcoming milestones include 2-year data from PRISM clinical trial and 18-month data from Phase 2b cohorts for 4D-150 in wet AMD. Interim data and program updates for 4D-710 in CF lung disease are expected in H2 2025. Financially, the company reported a cash position of $505 million as of December 31, 2024, with R&D expenses of $141.3 million in 2024. Net loss for 2024 was $160.9 million.

4D Molecular Therapeutics is a biotechnology company developing durable therapeutics like 4D-150 for retinal vascular diseases and 4D-710 for CF. The company’s focus is on advancing its product candidates through clinical trials and optimizing resources for future development. Forward-looking statements highlight the potential benefits of their therapies and future milestones.



Read more at GlobeNewswire:: 4DMT Reports Full Year 2024 Financial Results, Operational